Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth L Hastings

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
International Immunopharmacology|November 16, 2002
Implications of the new FDA/CDER immunotoxicology guidance for drugsKenneth L Hastings,
Expert Opinion on Drug Metabolism & Toxicology|July 25, 2006
The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonistsKenneth L Hastings
Critical Reviews in Toxicology|April 21, 2005
Commentary on hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implicationsKenneth L Hastings
Methods in Molecular Biology (Clifton, N.J.)|June 9, 2018
Immunotoxicology: A Brief HistoryKenneth L Hastings
Journal of Immunotoxicology|October 30, 2008
Prospects for developmental immunotoxicity guidance and an update on ICH S8Kenneth L Hastings
Journal of Immunotoxicology|October 30, 2008
Multidimensional immunomodulationRobert V House, Kenneth L Hastings
International Journal of Toxicology|June 2, 2009
Acknowledgement of contributions of Dr. Harihara Mehendale as editor-in-chief of International Journal of ToxicologyKenneth L Hastings, A Wallace Hayes
Toxicology|March 16, 2005
Clinical relevance of preclinical testing for allergic side effectsShukal Bala, James Weaver, Kenneth L Hastings
Expert Opinion on Drug Safety|June 16, 2006
Drug-induced phospholipidosis: issues and future directionsMark J Reasor, Kenneth L Hastings, Roger G Ulrich
International Journal of Toxicology|December 27, 2019
Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case ExamplesNicola J Stagg, Hanan N Ghantous, Robert Roth, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
International Immunopharmacology|November 16, 2002
Implications of the new FDA/CDER immunotoxicology guidance for drugsKenneth L Hastings,
Expert Opinion on Drug Metabolism & Toxicology|July 25, 2006
The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonistsKenneth L Hastings
Critical Reviews in Toxicology|April 21, 2005
Commentary on hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implicationsKenneth L Hastings
Methods in Molecular Biology (Clifton, N.J.)|June 9, 2018
Immunotoxicology: A Brief HistoryKenneth L Hastings
Journal of Immunotoxicology|October 30, 2008
Prospects for developmental immunotoxicity guidance and an update on ICH S8Kenneth L Hastings
Journal of Immunotoxicology|October 30, 2008
Multidimensional immunomodulationRobert V House, Kenneth L Hastings
International Journal of Toxicology|June 2, 2009
Acknowledgement of contributions of Dr. Harihara Mehendale as editor-in-chief of International Journal of ToxicologyKenneth L Hastings, A Wallace Hayes
Toxicology|March 16, 2005
Clinical relevance of preclinical testing for allergic side effectsShukal Bala, James Weaver, Kenneth L Hastings
Expert Opinion on Drug Safety|June 16, 2006
Drug-induced phospholipidosis: issues and future directionsMark J Reasor, Kenneth L Hastings, Roger G Ulrich
International Journal of Toxicology|December 27, 2019
Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case ExamplesNicola J Stagg, Hanan N Ghantous, Robert Roth, et al.
Pageof 3